| The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin V Quagliariello, M De Laurentiis, D Rea, A Barbieri, MG Monti, A Carbone, ... Cardiovascular diabetology 20, 1-20, 2021 | 229 | 2021 |
| Targeting histone deacetylases in diseases: where are we? R Benedetti, M Conte, L Altucci Antioxidants & redox signaling 23 (1), 99-126, 2015 | 182 | 2015 |
| Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes A Nebbioso, F Manzo, M Miceli, M Conte, L Manente, A Baldi, A De Luca, ... EMBO reports 10 (7), 776-782, 2009 | 174 | 2009 |
| Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities P Bontempo, L Mita, M Miceli, A Doto, A Nebbioso, F De Bellis, M Conte, ... The international journal of biochemistry & cell biology 39 (10), 1902-1914, 2007 | 150 | 2007 |
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities D Rotili, S Tomassi, M Conte, R Benedetti, M Tortorici, G Ciossani, ... Journal of medicinal chemistry 57 (1), 42-55, 2014 | 134 | 2014 |
| c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer A Nebbioso, V Carafa, M Conte, FP Tambaro, C Abbondanza, J Martens, ... Clinical Cancer Research 23 (10), 2542-2555, 2017 | 130 | 2017 |
| HDAC inhibitors as epigenetic regulators for cancer immunotherapy M Conte, R De Palma, L Altucci The international journal of biochemistry & cell biology 98, 65-74, 2018 | 75 | 2018 |
| Bisphenol A induces cell cycle arrest in primary and prostate cancer cells through EGFR/ERK/p53 signaling pathway activation A Bilancio, P Bontempo, M Di Donato, M Conte, P Giovannelli, L Altucci, ... Oncotarget 8 (70), 115620, 2017 | 66 | 2017 |
| Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors A Mai, S Valente, D Cheng, A Perrone, R Ragno, S Simeoni, G Sbardella, ... ChemMedChem: Chemistry Enabling Drug Discovery 2 (7), 987-991, 2007 | 63 | 2007 |
| Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities JA Souto, M Conte, R Álvarez, A Nebbioso, V Carafa, L Altucci, ... ChemMedChem: Chemistry Enabling Drug Discovery 3 (9), 1435-1442, 2008 | 60 | 2008 |
| Indole-derived psammaplin A analogues as epigenetic modulators with multiple inhibitory activities R Pereira, R Benedetti, S Perez-Rodriguez, A Nebbioso, ... Journal of Medicinal Chemistry 55 (22), 9467-9491, 2012 | 55 | 2012 |
| Epigenetic-based therapy: From single-to multi-target approaches R Benedetti, M Conte, C Iside, L Altucci The international journal of biochemistry & cell biology 69, 121-131, 2015 | 51 | 2015 |
| HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b I Lepore, C Dell’Aversana, M Pilyugin, M Conte, A Nebbioso, F De Bellis, ... PLoS One 8 (12), e83018, 2013 | 48 | 2013 |
| TNF-related apoptosis-inducing ligand: signalling of a ‘smart’molecule F Manzo, A Nebbioso, M Miceli, M Conte, F De Bellis, V Carafa, G Franci, ... The international journal of biochemistry & cell biology 41 (3), 460-466, 2009 | 47 | 2009 |
| Discovery of the first-in-class GSK-3β/HDAC dual inhibitor as disease-modifying agent to combat Alzheimer’s disease A De Simone, V La Pietra, N Betari, N Petragnani, M Conte, S Daniele, ... ACS Medicinal Chemistry Letters 10 (4), 469-474, 2019 | 46 | 2019 |
| Molecular analysis of the apoptotic effects of BPA in acute myeloid leukemia cells P Bontempo, L Mita, A Doto, M Miceli, A Nebbioso, I Lepore, GL Franci, ... Journal of translational medicine 7, 1-8, 2009 | 43 | 2009 |
| Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents M Brindisi, C Ulivieri, G Alfano, S Gemma, F de Asís Balaguer, T Khan, ... European journal of medicinal chemistry 162, 290-320, 2019 | 35 | 2019 |
| Context-selective death of acute myeloid leukemia cells triggered by the novel hybrid retinoid-HDAC inhibitor MC2392 F De Bellis, V Carafa, M Conte, D Rotili, F Petraglia, F Matarese, ... Cancer research 74 (8), 2328-2339, 2014 | 35 | 2014 |
| Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances M Conte, L Altucci Clinical Cancer Research 18 (20), 5526-5534, 2012 | 33 | 2012 |
| ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias L D’Amato, C Dell’Aversana, M Conte, A Ciotta, L Scisciola, A Carissimo, ... Epigenetics 10 (1), 6-18, 2015 | 32 | 2015 |
